PDF(Pubmed)
Abstract：
Neonatal disorders, particularly those resulting from prematurity, pose a major challenge in health care and have a significant impact on infant mortality and long-term child health. The limitations of current therapeutic strategies emphasize the need for innovative treatments. New cell-free technologies utilizing extracellular vesicles (EVs) offer a compelling opportunity for neonatal therapy by harnessing the inherent regenerative capabilities of EVs. These nanoscale particles, secreted by a variety of organisms including animals, bacteria, fungi and plants, contain a repertoire of bioactive molecules with therapeutic potential. This review aims to provide a comprehensive assessment of the therapeutic effects of EVs and mechanistic insights into EVs from stem cells, biological fluids and non-animal sources, with a focus on common neonatal conditions such as hypoxic-ischemic encephalopathy, respiratory distress syndrome, bronchopulmonary dysplasia and necrotizing enterocolitis. This review summarizes evidence for the therapeutic potential of EVs, analyzes evidence of their mechanisms of action and discusses the challenges associated with the implementation of EV-based therapies in neonatal clinical practice.
摘要：
新生儿疾病,特别是那些因早产而产生的，在卫生保健方面构成重大挑战，并对婴儿死亡率和长期儿童健康产生重大影响。当前治疗策略的局限性强调了对创新治疗的需求。利用细胞外囊泡（EV）的新无细胞技术通过利用EV固有的再生能力为新生儿治疗提供了令人信服的机会。这些纳米级颗粒，由包括动物在内的各种生物分泌，细菌,真菌和植物，含有一系列具有治疗潜力的生物活性分子。这篇综述旨在全面评估电动汽车的治疗效果，以及从干细胞对电动汽车的机制见解。生物流体和非动物来源，重点关注新生儿常见的疾病，如缺氧缺血性脑病，呼吸窘迫综合征,支气管肺发育不良和坏死性小肠结肠炎。这篇综述总结了电动汽车治疗潜力的证据，分析其作用机制的证据，并讨论与在新生儿临床实践中实施基于EV的治疗相关的挑战。
